Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre study

Traumatic brain injury is a leading cause of death and disability worldwide. The nitric oxide synthase inhibitor Ronopterin was shown to improve clinical outcome by enhancing neuroprotection in a phase IIa trial.

Saved in:
Bibliographic Details
Main Authors: Tegtmeier, Frank (Author) , Unterberg, Andreas (Author)
Format: Article (Journal)
Language:English
Published: 12 February 2020
In: Trials
Year: 2020, Volume: 21, Pages: 1
ISSN:1468-6694
DOI:10.1186/s13063-020-4107-8
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s13063-020-4107-8
Get full text
Author Notes:Frank Tegtmeier, Reinhard Schinzel, Ronny Beer, Diederik Bulters, Jean-Yves LeFrant, Joan Sahuquillo, Andreas Unterberg, Peter Andrews, Antonio Belli, Javier Ibanez, Alfonso Lagares, Michael Mokry, Harald Willschke, Charlotte Flüh, Erich Schmutzhard and on behalf of the NOSTRA Investigators

MARC

LEADER 00000caa a2200000 c 4500
001 169382616X
003 DE-627
005 20220818030415.0
007 cr uuu---uuuuu
008 200402s2020 xx |||||o 00| ||eng c
024 7 |a 10.1186/s13063-020-4107-8  |2 doi 
035 |a (DE-627)169382616X 
035 |a (DE-599)KXP169382616X 
035 |a (OCoLC)1341313516 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Tegtmeier, Frank  |e VerfasserIn  |0 (DE-588)1207493155  |0 (DE-627)1693824086  |4 aut 
245 1 0 |a Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial)  |b study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre study  |c Frank Tegtmeier, Reinhard Schinzel, Ronny Beer, Diederik Bulters, Jean-Yves LeFrant, Joan Sahuquillo, Andreas Unterberg, Peter Andrews, Antonio Belli, Javier Ibanez, Alfonso Lagares, Michael Mokry, Harald Willschke, Charlotte Flüh, Erich Schmutzhard and on behalf of the NOSTRA Investigators 
264 1 |c 12 February 2020 
300 |a 1 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 02.04.2020 
520 |a Traumatic brain injury is a leading cause of death and disability worldwide. The nitric oxide synthase inhibitor Ronopterin was shown to improve clinical outcome by enhancing neuroprotection in a phase IIa trial. 
700 1 |a Unterberg, Andreas  |e VerfasserIn  |0 (DE-588)1032681187  |0 (DE-627)738641200  |0 (DE-576)168441233  |4 aut 
773 0 8 |i Enthalten in  |t Trials  |d London : BioMed Central, 2000  |g 21(2020), Artikel-ID 172, Seite 1  |h Online-Ressource  |w (DE-627)326173552  |w (DE-600)2040523-6  |w (DE-576)107014556  |x 1468-6694  |7 nnas  |a Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial) study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre study 
773 1 8 |g volume:21  |g year:2020  |g elocationid:172  |g pages:1  |g extent:1  |a Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial) study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre study 
787 0 8 |i Errata zu  |a Tegtmeier, Frank  |t Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial)  |d 2020  |w (DE-627)1693824558 
856 4 0 |u https://doi.org/10.1186/s13063-020-4107-8  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210518 
993 |a Article 
994 |a 2020 
998 |g 1032681187  |a Unterberg, Andreas  |m 1032681187:Unterberg, Andreas  |d 910000  |d 911200  |e 910000PU1032681187  |e 911200PU1032681187  |k 0/910000/  |k 1/910000/911200/  |p 7 
999 |a KXP-PPN169382616X  |e 3929367521 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"relHost":[{"origin":[{"publisherPlace":"London","publisher":"BioMed Central","dateIssuedKey":"2000","dateIssuedDisp":"2000-"}],"titleAlt":[{"title":"Current controlled trials in cardiovascular medicine"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial) study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre studyTrials","id":{"issn":["1468-6694","1745-6215"],"zdb":["2040523-6"],"eki":["326173552"]},"note":["Gesehen am 26.09.22"],"title":[{"title_sort":"Trials","title":"Trials"}],"pubHistory":["1.2000 -"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"326173552","part":{"extent":"1","text":"21(2020), Artikel-ID 172, Seite 1","volume":"21","pages":"1","year":"2020"}}],"recId":"169382616X","name":{"displayForm":["Frank Tegtmeier, Reinhard Schinzel, Ronny Beer, Diederik Bulters, Jean-Yves LeFrant, Joan Sahuquillo, Andreas Unterberg, Peter Andrews, Antonio Belli, Javier Ibanez, Alfonso Lagares, Michael Mokry, Harald Willschke, Charlotte Flüh, Erich Schmutzhard and on behalf of the NOSTRA Investigators"]},"physDesc":[{"extent":"1 S."}],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"12 February 2020"}],"person":[{"family":"Tegtmeier","display":"Tegtmeier, Frank","given":"Frank","role":"aut"},{"family":"Unterberg","display":"Unterberg, Andreas","role":"aut","given":"Andreas"}],"id":{"doi":["10.1186/s13063-020-4107-8"],"eki":["169382616X"]},"title":[{"title":"Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial)","title_sort":"Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial)","subtitle":"study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre study"}],"note":["Gesehen am 02.04.2020"]} 
SRT |a TEGTMEIERFCORRECTION1220